John Libbey Eurotext

Epileptic Disorders

The Educational Journal of the

Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam Volume 14, issue 2, June 2012

Figures

See all figures

Authors
Epilepsy Center, Neurological Institute, University Hospitals Case Medical Center, Cleveland, Ohio, Department of Emergency Medicine, University Hospitals Case Medical Center, Cleveland, Ohio, Department of Pediatrics, Division of Pediatric Epilepsy, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA
  • Key words: Gaucher disease, myoclonic status epilepticus, progressive myoclonus epilepsy, levetiracetam, myoclonic seizures, EEG
  • DOI : 10.1684/epd.2012.0501
  • Page(s) : 155-8
  • Published in: 2012

We present the first reported case of a rapid clinical and electroencephalographic response to intravenous levetiracetam infusion of myoclonic status epilepticus in a patient with progressive myoclonus epilepsy due to Gaucher disease. Under continuous video-EEG monitoring, the clinical myoclonic status and the electrographic ictal discharges resolved within 10 minutes after the infusion was initiated. The patient tolerated the treatment well without any reported side effects. This case suggests that levetiracetam may be a safe, effective, and well tolerated intravenous drug in patients with metabolic myoclonic status epilepticus such as Gaucher disease.